Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.

Aine McKillop, NA Duffy, JR Lindsay, BD Green, Steven Patterson, Finbarr O'Harte, PM Bell, Peter Flatt

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND: Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design. RESULTS: Plasma glucose reached 18.2+/-1.7 and 16.7+/-1.7 mmol/l at 90 min in control and placebo groups (P
Original languageEnglish
Pages (from-to)877-885
JournalEuropean Journal of Endocrinology
Volume16
Issue number6
DOIs
Publication statusPublished - 15 Sep 2009

Fingerprint Dive into the research topics of 'Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.'. Together they form a unique fingerprint.

  • Cite this